SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (“OncoVista”) (OTC BB: OVIT.OB) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced that the CTRC’s Institute for Drug Development will collaborate on early phase studies of OncoVista’s OVI-117, an L-nucleoside conjugate of 5-fluorodeoxyuridine monophosphate (FdUMP), an analog of 5-FU, in various solid tumor cancer indications. This work is in addition to a Phase I/II Study of Cordycepin plus Pentostatin in Patients with Refractory TdT-Positive Leukemia, sponsored by OncoVista that is currently underway at the CTRC.
